Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer * Stage IB (T2, N0), II (T1 or T2, N1 or T3, N0), or IIIA (T3, N1) * Potentially resectable disease * No large central primary tumors in proximity to significant blood vessels * No bronchoscopically evident endobronchial tumors * At least 1 unidimensionally measurable lesion * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan * No known brain metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-1 OR * Karnofsky 70-100% Life expectancy: * More than 12 months Hematopoietic: * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * No history of an inherited bleeding disorder * No inherited predisposition to a hypercoagulable state * No clinically evident hypercoagulable state or bleeding diathesis Hepatic: * Bilirubin less than 1.5 times upper limit of normal (ULN) * AST/ALT no greater than 2.5 times ULN * INR less than 1.5 * PTT less than 36 seconds Renal: * Creatinine less than 1.5 times ULN OR * Creatinine clearance at least 60 mL/min * No nephrotic syndrome * Urine protein no greater than 0.5 g/24 hours Cardiovascular: * No poorly controlled hypertension (greater than 150 mm Hg systolic and/or greater than 100 mm Hg diastolic) despite treatment * No uncompensated coronary artery disease * No myocardial infarction within the past 6 months * No clinically significant or severe peripheral vascular disease * No inherited predisposition to thrombosis * No deep venous or arterial thrombosis * No symptomatic congestive heart failure * No unstable angina pectoris within the past 6 months * No cardiac arrhythmia * No transient ischemic attack within the past 6 months * No cerebrovascular accident within the past 6 months * No other arterial thromboembolic event within the past 6 months Pulmonary: * No hemoptysis * No pulmonary embolism Other: * No history of allergic reactions to compounds of similar chemical or biologic composition to study drugs * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No psychiatric illness or social situation that would preclude study compliance * No significant traumatic injury within the past 28 days * No uncontrolled concurrent illness * No ongoing or active infection * No serious, non-healing wound, ulcer, or bone fracture * No other active malignancy * No requirement for full-dose anticoagulation or thrombolytic therapy PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior biologic therapy for this cancer * No concurrent prophylactic growth factors (e.g., epoetin alfa, filgrastim \[G-CSF\], or sargramostim \[GM-CSF\]) Chemotherapy: * No prior chemotherapy for this cancer * Prior chemotherapy for another malignancy allowed provided the prior malignancy was curatively treated and is currently controlled Endocrine therapy: * No prior endocrine therapy for this cancer Radiotherapy: * No prior radiotherapy for this cancer * Prior radiotherapy for another malignancy allowed provided the prior malignancy was curatively treated and is currently controlled * No concurrent radiotherapy Surgery: * Prior diagnostic bronchoscopy, mediastinoscopy, or CT-guided biopsy allowed * At least 28 days since prior major surgical procedure or open biopsy Other: * No other concurrent investigational agents * No other concurrent anticancer investigational or commercial agents or therapies * No concurrent combination antiretroviral therapy for HIV-positive patients * Concurrent low-dose warfarin for maintenence of preexisting, permanent, indwelling IV catheters allowed provided INR less than 1.5